OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Zealand Pharma A/S/  DK0060257814  /

Cboe Europe CXE
2024-05-02  10:56:26 AM Chg. - Volume Bid9:00:02 AM Ask9:00:02 AM High Low
622.25DKK - 57
Turnover: 35,468.25		 -Bid Size: - -Ask Size: - 622.25 622.25
GlobeNewswire 7:00 AM Zealand Pharma Announces Financial Results for the First Quarter of 2024
GlobeNewswire 05-09 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire 03-20 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire 03-01 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
GlobeNewswire 02-27 Zealand Pharma Announces Financial Results for the Full Year 2023
TeleTrader 02-26 Zealand Pharma soars 30% on positive weight-loss drug results
GlobeNewswire 02-26 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire 02-26 Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...
GlobeNewswire 02-20 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financia...
GlobeNewswire 01-19 Zealand Pharma major shareholder announcement: J O Hambro Capital Management
GlobeNewswire 01-17 Zealand Pharma major shareholder announcement: J O Hambro Capital Management
GlobeNewswire 01-12 Zealand Pharma completes registration of capital increase
GlobeNewswire 01-10 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
GlobeNewswire 01-08 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
GlobeNewswire 01-02 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on Janua...
GlobeNewswire 2023-12-23 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyp...
GlobeNewswire 2023-12-22 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
GlobeNewswire 2023-12-22 Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
GlobeNewswire 2023-12-04 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
GlobeNewswire 2023-11-30 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
GlobeNewswire 2023-11-09 Zealand Pharma Announces Financial Results for the First Nine Months of 2023
GlobeNewswire 2023-11-07 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
GlobeNewswire 2023-11-03 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 resul...
GlobeNewswire 2023-10-17 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek
GlobeNewswire 2023-10-05 Phase III studies to investigate survodutide for people living with obesity and overweight, with and...